Format

Send to

Choose Destination
BMC Neurol. 2015 Feb 5;15:8. doi: 10.1186/s12883-015-0260-1.

Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer's disease.

Author information

1
Brain Disease Biomarker Unit, Department of Experimental Medical Science, Wallenberg Neuroscience Center, Lund University, Lund, Sweden. Edina.Silajdzic@med.lu.se.
2
Brain Disease Biomarker Unit, Department of Experimental Medical Science, Wallenberg Neuroscience Center, Lund University, Lund, Sweden. Maria.Bjorkqvist@med.lu.se.
3
Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Malmö, Sweden. Oskar.Hansson@med.lu.se.
4
Memory Clinic, Skåne University Hospital, Malmö, Sweden. Oskar.Hansson@med.lu.se.

Abstract

BACKGROUND:

Phosphorylcholine is one of the major epitopes of oxidised low density lipoprotein. Low levels of IgM antibodies against phosphorylcholine (anti-PC) are associated with development of myocardial infarction and stroke. It has been shown that patients with Alzheimer's disease and other dementias have significantly lower serum anti-PC levels compared to controls, suggesting that low levels of atheroprotective anti-PC may play a role in AD and dementia.

METHODS:

We quantified levels of anti-PC levels using an ELISA in plasma from 176 controls, 125 patients with Alzheimer's disease, 19 patients with vascular dementia and 63 patients with other dementias.

RESULTS:

We observed similar plasma anti-PC levels in controls, patients with Alzheimer's disease, and other dementias.

CONCLUSIONS:

Our data suggests that anti-PC is not useful as a biomarker for Alzheimer's disease.

PMID:
25651913
PMCID:
PMC4324431
DOI:
10.1186/s12883-015-0260-1
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center